RecruitingNot ApplicableNCT04504604

TCF-001 TRACK (Target Rare Cancer Knowledge) Study

Sponsor

TargetCancer Foundation

Enrollment

400 participants

Start Date

Oct 1, 2020

Study Type

INTERVENTIONAL

Conditions

Cholangiocarcinoma Rare Cancers Cancer of Unknown Primary Site

Summary

This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study collects blood samples from people with rare solid tumors or rare lymphomas to look for cancer markers in the blood (called liquid biopsy). The goal is to improve early detection and monitoring for cancers that are too rare to study in large trials. **You may be eligible if...** - You are 18 or older - You have been diagnosed with a rare solid tumor or lymphoma (defined as fewer than 6 cases per 100,000 people per year) - Your cancer is measurable (evaluable disease at baseline) - You are willing to provide blood samples over time **You may NOT be eligible if...** - Your cancer is not considered rare by the study's definition - You are unable or unwilling to comply with the study's blood draw schedule - You cannot provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTFoundationOne CDx and FoundationOne Liquid CDx

Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.